EGR1 and sarcoma: In p53-deficient osteogenic sarcoma cells, the pro-survival pathway of MAPK/Akt/Nrf2/Egr1/hemoxygenase-1/glutamate cysteine ligase was shown to reduce 15-deoxy-D12,14-PGJ2 (a stable prostaglandin D2 degradation product) -mediated apoptosis [37].